CLAIMS

I (We) claim:

1. A capsule formulation comprising:

an encapsulated material comprising {[(1*R*,2*R*)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1*H*-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing; and

a capsule shell not comprising gelatin~~.~~;

wherein the capsule shell is formed with a capsule shell base comprising starch, pullulan, polyvinyl alcohol or hypromellose.

~~2. The capsule formulation according to claim 1, wherein the capsule shell is formed with a capsule shell base comprising starch, pullulan, polyvinyl alcohol or hypromellose.~~

~~3~~2. The capsule formulation according to claim 1, wherein the capsule shell is formed with a capsule shell base comprising pullulan or hypromellose.

~~4~~3. The capsule formulation according to claim 1, wherein the capsule shell is formed with a capsule shell base comprising hypromellose.

~~5~~4. The capsule formulation according to any of claims 1 to ~~4~~3, wherein the {[(1*R*,2*R*)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1*H*-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or the pharmacologically acceptable salt thereof, or the solvate of any of the foregoing is L-lysine-{[(1*R*,2*R*)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1*H*-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate-ethanol (1/1/1).

~~6~~5. The capsule formulation according to any of claims 1 to ~~5~~4, wherein the encapsulated material further comprises magnesium oxide.